U.S. Markets closed
  • S&P 500

    4,482.73
    -50.03 (-1.10%)
     
  • Dow 30

    34,715.39
    -313.21 (-0.89%)
     
  • Nasdaq

    14,154.02
    -186.28 (-1.30%)
     
  • Russell 2000

    2,024.04
    -38.74 (-1.88%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,839.50
    -3.10 (-0.17%)
     
  • Silver

    24.42
    -0.30 (-1.20%)
     
  • EUR/USD

    1.1311
    -0.0006 (-0.0566%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • Vix

    25.59
    +1.74 (+7.30%)
     
  • GBP/USD

    1.3583
    -0.0017 (-0.1236%)
     
  • USD/JPY

    113.8400
    -0.2600 (-0.2279%)
     
  • BTC-USD

    41,053.32
    -780.98 (-1.87%)
     
  • CMC Crypto 200

    969.42
    -25.84 (-2.60%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,229.05
    -543.85 (-1.96%)
     

Moderna to Present at Upcoming Investor Conferences in December 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MRNA
  • VCRRX

CAMBRIDGE, Mass., November 22, 2021--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

  • NASDAQ 45th Investor Conference on Wednesday, December 1st at 9:30 a.m. ET

  • Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1st at 2:00 p.m. ET

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006214/en/

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com